I. Graham

Cardiology and Cardiovascular Medicine · European Heart Journal · 2003–2022

A researcher in the Science corpus: 21 papers; trusts 40 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

Whom I. Graham trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. P. P. Toth
  2. M. Law
  3. F. He
  4. Børge G. Nordestgaard
  5. G. Assmann
  6. J. Despres
  7. Marc A. F. De Hert
  8. D. Mozaffarian
  9. A. Khera
  10. J. Davignon

Who trusts I. Graham overall

  1. S. Tsimikas
  2. G. Russo
  3. Børge G. Nordestgaard

Papers from I. Graham's perspective

Ordered by how strongly the researchers I. Graham trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Statin safety: a systematic review. (American Journal of Cardiology)
  2. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study (Circulation)
  3. Rosuvastatin in older patients with systolic heart failure. (Current Atherosclerosis Reports)
  4. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study (Cardiovascular Drugs and Therapy)
  5. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. (New England Journal of Medicine)
  6. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
  7. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. (The Lancet)
  8. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology (Statistics in Medicine)
  9. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. (Journal of the American College of Cardiology)
  10. Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (Journal of the American Pharmacists Association)

Their papers